Ovarian Neoplasms

"Ovarian Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.

Descriptor ID	D010051
MeSH Number(s)	C04.588.322.455 C13.351.500.056.630.705 C13.351.937.418.685 C19.344.410 C19.391.630.705
Concept/Terms	Ovarian Neoplasms Ovarian Neoplasms Neoplasm, Ovarian Ovarian Neoplasm Ovary Neoplasms Neoplasm, Ovary Neoplasms, Ovary Ovary Neoplasm Neoplasms, Ovarian Ovary Cancer Ovary Cancer Cancer, Ovary Cancers, Ovary Ovary Cancers Ovarian Cancer Cancer, Ovarian Cancers, Ovarian Ovarian Cancers Cancer of Ovary Cancer of the Ovary

Below are MeSH descriptors whose meaning is more general than "Ovarian Neoplasms".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Endocrine Gland Neoplasms [C04.588.322]
Ovarian Neoplasms [C04.588.322.455]
Female Urogenital Diseases and Pregnancy Complications [C13]
Female Urogenital Diseases [C13.351]
Genital Diseases, Female [C13.351.500]
Adnexal Diseases [C13.351.500.056]
Ovarian Diseases [C13.351.500.056.630]
Ovarian Neoplasms [C13.351.500.056.630.705]
Urogenital Neoplasms [C13.351.937]
Genital Neoplasms, Female [C13.351.937.418]
Ovarian Neoplasms [C13.351.937.418.685]
Endocrine System Diseases [C19]
Endocrine Gland Neoplasms [C19.344]
Ovarian Neoplasms [C19.344.410]
Gonadal Disorders [C19.391]
Ovarian Diseases [C19.391.630]
Ovarian Neoplasms [C19.391.630.705]

Below are MeSH descriptors whose meaning is more specific than "Ovarian Neoplasms".

Ovarian Neoplasms
Granulosa Cell Tumor
Hereditary Breast and Ovarian Cancer Syndrome
Luteoma
Meigs Syndrome
Sertoli-Leydig Cell Tumor
Thecoma

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Ovarian Neoplasms" by people in this website by year, and whether "Ovarian Neoplasms" was a major or minor topic of these publications.

Bar chart showing 110 publications over 29 distinct years, with a maximum of 9 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
1996	2	0	2
1997	2	0	2
1998	1	2	3
1999	3	2	5
2001	2	0	2
2002	2	2	4
2003	2	0	2
2004	2	0	2
2005	4	1	5
2006	2	1	3
2007	2	0	2
2008	5	0	5
2009	5	3	8
2010	1	0	1
2011	4	1	5
2012	1	0	1
2013	3	2	5
2014	2	2	4
2015	3	0	3
2016	3	0	3
2017	1	3	4
2018	3	0	3
2019	6	0	6
2020	3	0	3
2021	9	0	9
2022	5	0	5
2023	6	0	6
2024	3	3	6

Below are the most recent publications written about "Ovarian Neoplasms" by people in Profiles.

MacGilvary N, Cantor SB. Positioning loss of PARP1 activity as the central toxic event in BRCA-deficient cancer. DNA Repair (Amst). 2024 Dec; 144:103775.

View in: PubMed
O'Malley DM, Myers T, Wimberger P, Van Gorp T, Redondo A, Cibula D, Nicum S, Rodrigues M, Backes FJ, Barlin JN, Lewin SN, Lim P, Pothuri B, Diver E, Banerjee S, Lorusso D. Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRa-high platinum-sensitive ovarian cancer. Future Oncol. 2024; 20(32):2423-2436.

View in: PubMed
Polan RM, Ali-Fehmi R, Grace AK, Mattei LH, Tanner EJ, Morris RT. Occult residual ovarian tissue at the time of minimally invasive risk reducing surgery in women with BRCA mutations. Gynecol Oncol. 2024 Oct; 189:37-40.

View in: PubMed
Mattei LH. The Maternal Crossroad. N Engl J Med. 2024 Jun 20; 390(23):2139-2141.

View in: PubMed
Mishra AK, Ye T, Banday S, Thakare RP, Su CT, Pham NNH, Ali A, Kulshreshtha A, Chowdhury SR, Simone TM, Hu K, Zhu LJ, Eisenhaber B, Deibler SK, Simin K, Thompson PR, Kelliher MA, Eisenhaber F, Malonia SK, Green MR. Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer. Cell Rep. 2024 04 23; 43(4):114041.

View in: PubMed
Zhou B, Kwan B, Desai MJ, Nalawade V, Henk J, Viravalli N, Murphy JD, Nathan PC, Ruddy KJ, Shliakhtsitsava K, Su HI, Whitcomb BW. Association of platinum-based chemotherapy with live birth and infertility in female survivors of adolescent and young adult cancer. Fertil Steril. 2024 Jun; 121(6):1020-1030.

View in: PubMed
Moore KN, Angelergues A, Konecny GE, Garc?a Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Est?vez-Garc?a P, Coffman L, Nicum S, Duska LR, Pignata S, G?lvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T. Mirvetuximab Soravtansine in FRa-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023 Dec 07; 389(23):2162-2174.

View in: PubMed
Kamat S, Brown BR, Hume A, Vyas A. Association of guideline-concordant care with survival, health care utilization, and costs among older women with advanced epithelial ovarian cancer. Am J Manag Care. 2023 10 01; 29(10):e292-e298.

View in: PubMed
Bobisse S, Bianchi V, Tanyi JL, Sarivalasis A, Missiaglia E, P?tremand R, Benedetti F, Torigian DA, Genolet R, Barras D, Michel A, Mastroyannis SA, Zsiros E, Dangaj Laniti D, Tsourti Z, Stevenson BJ, Iseli C, Levine BL, Speiser DE, Gfeller D, Bassani-Sternberg M, Powell DJ, June CH, Dafni U, Kandalaft LE, Harari A, Coukos G. A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer. Nat Cancer. 2023 Oct; 4(10):1410-1417.

View in: PubMed
Pignata S, Bookman M, Sehouli J, Miller A, Penson RT, Taskiran C, Anderson C, Hietanen S, Myers T, Madry R, Willmott L, Lortholary A, Thomes-Pepin J, Aghajanian C, McCourt C, Stuckey A, Wu X, Nishio S, Copeland LJ, He Y, Molinero L, Patel S, Lin YG, Khor VK, Moore KN. Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer. Gynecol Oncol. 2023 10; 177:20-31.

View in: PubMed

People

Explore

Similar Concepts

Top Journals